Active Ingredient History

NOW
  • Now
Darusentan is an endothelin receptor antagonist. Gilead Colorado, a subsidiary of Gilead Sciences, under license from Abbott Laboratories, is developing darusentan for the potential treatment of uncontrolled hypertension.   Wikipedia

  • SMILES: COc1cc(OC)nc(O[C@H](C(=O)O)C(OC)(c2ccccc2)c3ccccc3)n1
  • InChIKey: FEJVSJIALLTFRP-LJQANCHMSA-N
  • Mol. Mass: 410.43
  • ALogP: 2.92
  • ChEMBL Molecule:
More Chemistry
2-(4,6-dimethoxypyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionic acid | benzenepropanoic acid, alpha-((4,6-dimethoxy-2-pyrimidinyl)oxy)-beta-methoxy-beta-phenyl-, (s)- | darusentan | hmr-4005 | lu 127043 | lu 135252 | lu-135252 | (+)-(s)-2-((4,6-dimethoxy-2-pyrimidinyl)oxy)-3-methoxy-3,3-diphenylpropionic acid

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue